Lemborexant
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
2
Recruiting
2
Completed
1
Sites
49
Countries
4
Endpoints
126
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 126 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 8 of 126 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
6
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT03001557Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia | Lemborexant Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 48 | Jul 2018 | - | results |
| NCT06274528DORA and LP in Alzheimer's Disease Biomarkers | Lemborexant Alzheimer’s disease | Age ≥65 | Ph 2 | Recruiting | 1 | Mar 2030 | - | |
| NCT05728736Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau | Lemborexant Alzheimer’s disease | Amyloid biomarker required (plasma) | Ph 2 | Withdrawn | 1 | Sep 2023 | - | |
| NCT06093126Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial | Lemborexant Frontotemporal dementia | - | Ph 4 | Recruiting | 1 | Dec 2028 | - |
Showing 1-4 of 4 trials